l-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats

Neurochemistry International

Volumn 49, Issue 1, 2006, Pages 28-40

  Saravanan, Karuppagounder S ^a   Sindhu, Kizhakke M ^a   Senthilkumar, Karuppagounder S ^a   Mohanakumar, Kochupurackal P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; ROTENONE; SELEGILINE; SUPEROXIDE DISMUTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CORPUS STRIATUM; CYTOSOL; DOPAMINERGIC SYSTEM; ELECTROCHEMISTRY; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; IMMUNOREACTIVITY; MALE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

AMPHETAMINE; ANIMALS; CATALASE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON TRANSPORT COMPLEX I; HYDROXYL RADICAL; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SELEGILINE; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; TYROSINE 3-MONOOXYGENASE; UNCOUPLING AGENTS; UP-REGULATION;

ANIMALIA;

EID: 33646527553     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2005.12.016     Document Type: Article

References (113)

1. Adams C.E., Hoffman A.F., Hudson J.L., Hoffer B.J., and Boyson S.J. Chronic treatment with levodopa and/or selegiline does not affect behavioral recovery induced by fetal ventral mesencephalic grafts in unilaterally 6-hydroxydopamine-lesioned rats. Exp. Neurol. 130 (1994) 261-268
2. Aebi H. Catalase in vitro. Methods Enzymol. 105 (1984) 121-126
3. Alam M., and Schmidt W.J. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136 (2002) 317-324
4. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69 (1997) 1196-1203
5. Alam M., Mayerhofer A., and Schmidt W.J. The neurobehavioral changes induced by bilateral rotenone lesion in medial forebrain bundle of rats are reversed by l-DOPA. Behav. Brain Res. 151 (2004) 117-124
6. Ansari K.S., Yu P.H., Kruck T.P., and Tatton W.G. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neurosci. 13 (1993) 4042-4053
7. Bashkatova V., Alam M., Vanin A., and Schmidt W.J. Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain. Exp. Neurol. 186 (2004) 235-241
8. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2 (2001) 325-334
9. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
10. Birkmeyer W., Knoll J., Riederer P., Hars V., and Marton J. Increased life expectancy resulting from addition of l-deprenyl to Mardopar treatment in Parkinson's disease: a long-term study. J. Neural Transm. 64 (1985) 113-127
11. Carrillo M.C., Kanai S., Nokubo M., and Kitani K. (-) Deprenyl induces activities of both superoxide dismutase and catalase but not of glutathione peroxidase in the striatum of young male rats. Life Sci. 48 (1991) 517-521
12. Carrillo M.C., Kitani K., Kanai S., Sato S., and Ivy G.O. The ability of (-)-deprenyl to increase superoxide dismutase activities in the rat is tissue and brain region selective. Life Sci. 50 (1992) 1985-1992
13. Cassarino D.S., and Bennett Jr. J.P. An evaluation of the role of mitochondria in neurodegenerative diseases: mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration. Brain Res. Rev. 29 (1999) 1-25
14. Chiueh C.C., Huang S.J., and Murphy D.L. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity. J. Neural Transm. Suppl. 41 (1994) 189-196
15. Cleeter M.W., Cooper J.M., and Schapira A.H. Irreversible inhibition of mitochondrial complex-I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement. J. Neurochem. 58 (1992) 786-789
16. Clow A., Hussain T., Glover V., Sandler M., Dexter D.T., and Walker M. (-) Deprenyl can induce soluble superoxide dismutase in rat striata. J. Neural Transm. Gen. Sect. 86 (1991) 77-80
17. Cohen G., and Spina M.B. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann. Neurol. 26 (1989) 689-690
18. Cohn V.H., and Lyle J. A fluorimetric assay for glutathione. Anal. Biochem. 14 (1966) 434-440
19. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., and Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114 (1991) 1953-1975
20. 2 and ATP production and on dopamine and DOPAC in the striatum. J. Physiol. Biochem. 55 (1999) 325-331
21. Fang J., and Yu P.H. Effect of l-deprenyl, its structural analogues and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33 (1994) 763-768
22. Ferger B., van Amsterdam C., Seyfried C., and Kuschinsky K. Effects of alpha-phenyl-tert-butylnitrone and selegiline on hydroxyl freeradicals in rat striatum produced by local application of glutamate. J. Neurochem. 70 (1998) 276-280
23. Ferrante R.J., Schulz J.B., Kowall N.W., and Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753 (1997) 157-162
24. Ferraro T.N., Golden G.T., DeMattei M., Hare T.A., and Fariello R.G. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydro pyridine (MPTP) on levels of glutathione in the extrapyramidal system of the mouse. Neuropharmacology 25 (1986) 1071-1074
25. Gerlach M., and Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J. Neural Transm. 103 (1996) 987-1041
26. Gluck M.R., Krueger M.J., Ramsay R.R., Sablin O.S., Singer T.P., and Nicklas W.J. Characterization of the inhibitory mechanism of MPP+ and 4-phenyl pyridine analogs in inner membrane preparations. J. Biol. Chem. 269 (1994) 3167-3174
27. Gotz M.E., Dirr A., Burger R., Rausch W.D., and Riederer P. High dose selegiline augments striatal ubiquinol in mouse: an indication of decreased oxidative stress or of interference with mitochondrial respiration? A pilot study. J. Neural Transm. 46 (1995) 149-156
28. Greenamyre J.T., MacKenzie G., Peng T.I., and Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66 (1999) 85-97
29. Halliwell B., and Gutteridge J. Oxygen radicals and the nervous system. Trends Neurosci. 8 (1985) 22-29
30. Haycock J.W. Stimulation-dependent phosphorylation of tyrosine hydroxylase in rat corpus striatum. Brain Res. Bull. 19 (1987) 619-622
31. Heikkila R.E., Nicklas W.J., Vyas I., and Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4-phenylpyridinium ion after their stereotaxic administration to rats: implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Neurosci. Lett. 62 (1985) 389-394
32. Hoglinger G.U., Feger J., Prigent A., Michel P.P., Parain K., Champy P., Ruberg M., Oertel W.H., and Hirsch E.C. Chronic systemic complex-I inhibition induces a hypokinetic multisystem degeneration in rats. J. Neurochem. 84 (2003) 491-502
33. Jenner P. Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta. Neurol. Scand. Suppl. 146 (1993) 6-13
34. Jenner P. Parkinson's disease, pesticides and mitochondrial dysfunction. Trends Neurosci. 24 (2001) 245-247
35. Jenner P., Dexter D.T., Sian J., Schapira A.H., and Marsden C.D. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann. Neurol. 32 (1992) S82-S87
36. Jha N., Jurma O., Lalli G., Liu Y., Pettus E.H., Greenamyre J.T., Liu R.M., Forman H.J., and Andersen J.K. Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex-I activity. Implications for Parkinson's disease. J. Biol. Chem. 275 (2000) 26096-26101
37. Khaldy H., Escames G., Leon J., Bikjdaouene L., and Acuna-Castroviejo D. Synergistic effects of melatonin and deprenyl against MPTP-inducedmitochondrial damage and DA depletion. Neurobiol. Aging 24 (2003) 491-500
38. Kitani K., Kanai S., Ivy G.O., and Carrillo M.C. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech. Ageing Dev. 111 (1999) 211-221
39. Kitani K., Minami C., Isobe K., Maehara K., Kanai S., Ivy G.O., and Carrillo M.C. Why (-) deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Dev. 123 (2002) 1000-1087
40. Knoll J. The pharmacology of (-) deprenyl. J. Neural Transm. Suppl. 22 (1986) 75-89
41. Knoll J. The striatal dopamine dependency of life span in male rats. Longevity study with (-) deprenyl. Mech. Ageing Dev. 46 (1988) 237-262
42. Knoll J. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity. Adv. Neurol. 53 (1990) 425-429
43. Knoll J. Pharmacological basis of the therapeutic effect of (-) deprenyl in age-related neurological disease. Med. Res. Rev. 12 (1992) 505-524
44. Knoll J. (-) Deprenyl (selegiline, a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 82 (1998) 57-66
45. Knoll J. Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives. Neurochem. Res. 28 (2003) 1275-1297
46. Knollema S., Aukema S., Hom H., Korf J., and Horst G.J.T. l-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26 (1995) 1883-1887
47. Kontkanen O., and Castren E. Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res. 829 (1999) 190-192
48. Lahtinen H., Koistinaho J., Kauppinen R., Haapalinna A., Keinanen R., and Sivenius J. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 757 (1997) 260-267
49. Li N., Ragheb K., Lawler G., Sturgis J., Rajwa B., Melendez J.A., and Robinson J.P. Mitochondrial complex-I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J. Biol. Chem. 278 (2003) 8516-8525
50. Liou H.H., Chen R.C., Chen T.H., Tsai Y.F., and Tsai M.C. Attenuation of paraquat-induced dopaminergic toxicity on the substantia nigra by (-) deprenyl in vivo. Toxicol. Appl. Pharmacol. 172 (2001) 37-43
51. Lotharius J., and O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation: a novel mechanism of toxicity. J. Biol. Chem. 275 (2000) 38581-38588
52. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
53. Maharaj D.S., Saravanan K.S., Maharaj H., Mohanakumar K.P., and Daya S. Acetaminophen and aspirin inhibit superoxide anion generation and lipid peroxidation, and protect against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Neurochem. Int. 44 (2004) 355-360
54. Maia F.D., Pitombeira B.S., Araujo D.T., Cunha G.M., and Viana G.S. l-deprenyl prevents lipid peroxidation and memory deficits produced by cerebral ischemia in rats. Cell Mol. Neurobiol. 24 (2004) 87-100
55. Marklund S., and Marklund G. Involvement of superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur. J. Biochem. 47 (1974) 469-474
56. Maruyama W., Akao Y., Carrillo M.C., Kitani K., Youdium M.B., and Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24 (2002) 675-682
57. + and β-carbolinium: a microdialysis study in rats. Neurosci. Lett. 302 (2001) 65-68
58. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., and Kagawa Y. Deficiencies in complex-I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163 (1989) 1450-1455
59. Mohanakumar K.P., and Muralikrishnan D. Neurochemical mechanisms underlying neuroprotective actions of bromocriptine, salicylate, d- and l-deprenyl in neurodegeneration caused by MPTP. In: Collins M.A., and Storch A. (Eds). Neurotoxic Factors in Parkinson's Disease and Related Disorders (2000), Kluwer Academic/Plenum Press, New York 289-294
60. Mohanakumar K.P., and Steinbusch H.W. Hydroxyl radicals and nitric oxide in neurotoxicity and neuroprotection. J. Chem. Neuroanat. 14 (1998) 125-127
61. Mohanakumar K.P., de Bartolomeis A., Wu R.M., Yeh K.J., Sternberger L.M., Peng S.Y., Murphy D.L., and Chiueh C.C. Ferrous-citrate complex and nigral degeneration: evidence for free radical formation and lipid peroxidation. Ann. NY Acad. Sci. 738 (1994) 392-399
62. Mohanakumar K.P., Muralikrishnan D., and Thomas B. Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Brain Res. 864 (2000) 281-290
63. Mohanakumar K.P., Thomas B., Sharma S.M., Muralikrishnan D., Chowdhury R., and Chiueh C.C. Nitric oxide: an antioxidant and neuroprotector. Ann. NY Acad. Sci. 962 (2002) 389-401
64. Muller T., Kuhn W., Kruger R., and Przuntek H. Selegiline as immunostimulant-a novel mechanism of action?. J. Neural Transm. Suppl. 52 (1996) 321-328
65. Muralikrishnan D., and Mohanakumar K.P. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice. FASEB J. 12 (1998) 905-912
66. Muralikrishnan D., Samantaray S., and Mohanakumar K.P. d-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. Synapse 50 (2003) 7-13
67. Mytilineou C., Leonardi E.K., Radcliffe P., Heinonew E.H., and Han S.K. Deprenyl and desmethylselegiline protect mesencephalic neurons from toxicity induced by glutathione depletion. J. Pharmacol. Exp. Ther. 284 (1998) 700-706
68. Nicklas W.J., Vyas I., and Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36 (1985) 2503-2508
69. Olanow C.W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16 (1993) 439-444
70. Olanow C.W. Deprenyl in the treatment of Parkinson's disease: clinical effects and speculations on mechanism of action. J. Neural Transm. 48 (1996) 75-84
71. Owen A.D., Schapira A.H., Jenner P., and Marsden C.D. Oxidative stress and Parkinson's disease. Ann. NY Acad. Sci. 786 (1996) 217-223
72. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. (1998), Academic Press, San Diego
73. 2+ homeostasis. Neurosci. Res. 37 (2000) 227-236
74. +. Biochem. Biophys. Res. Commun. 134 (1986) 743-748
75. Rodriguez-Gomez J.A., Venero J.L., Vizuete M.L., Cano J., and Machado A. Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system. Mol. Brain Res. 46 (1997) 31-38
76. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966 (2003) 245-252
77. Salo P.T., and Tatton W.G. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31 (1992) 394-400
78. Salonen T., Haapalinna A., Heinonen E., Suhonen J., and Hervonen A. Monoamine oxidase B inhibitor selegiline protects young and aged rat peripheral sympathetic neurons against 6-hydroxydopamine-induced neurotoxicity. Acta Neuropathol. 91 (1996) 466-474
79. Saravanan K.S., Sindhu K.M., and Mohanakumar K.P. Acute intranigral infusion of rotenone in rats causes progressive biochemical lesions in the striatum similar to Parkinson's disease. Brain Res. 1049 (2005) 147-155
80. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex-I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
81. Schuler F., and Casida J.E. Functional coupling of PSST and ND1 subunits in NADH:ubiquinone oxidoreductase established by photoaffinity labeling. Biochim. Biophys. Acta. 1506 (2001) 79-87
82. Schwarting R.K., and Huston J.P. The unilateral 6-hydroxydopamine-lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog. Neurobiol. 50 (1996) 275-331
83. Semkova I., Wolz P., Schilling M., and Krieglstein J. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur. J. Pharmacol. 315 (1996) 19-30
84. Sharma S.K., and Ebadi M. Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid. Redox Signal. 5 (2003) 251-264
85. Sheehan J.P., Swerdlow R.H., Parker W.D., Miller S.W., Davis R.E., and Tuttle J.B. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J. Neurochem. 68 (1997) 1221-1233
86. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
87. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
88. Shults C.W., Nasirian F., Ward D.M., Nakano K., Pay M., Hill L.R., and Haas R.H. Carbidopa/levodopa and selegiline do not affect platelet mitochondrial function in early parkinsonism. Neurology 45 (1995) 344-348
89. Sindhu K.M., Saravanan K.S., and Mohanakumar K.P. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res. 1051 (2005) 25-34
90. Takahata, K., Shimazu, S., Katsuki, H., Yoneda, F., Akaike, A., 2006. Effects of selegiline on antioxidant systems in the nigrostriatum in rat, J. Neural Transm. 113, 151-158.
91. Tang Y.P., Ma Y.L., Chao C.C., Chen K.Y., and Lee E.H. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-) deprenyl and melatonin treatments. J. Neurosci. Res. 53 (1998) 593-604
92. Tatton W.G., and Chalmers-Redman R.M. Modulation of gene expression rather than monoamine oxidase inhibition: (-) deprenyl-related compounds in controlling neurodegeneration. Neurology 47 (1996) S171-S183
93. Tatton W.G., Chalmers-Redman R.M., Ju W.J., Mammen M., Carlile G.W., Pong A.W., and Tatton N.A. Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J. Pharmacol. Exp. Ther. 301 (2002) 753-764
94. Testa C.M., Sherer T.B., and Greenamyre J.T. Rotenone induces oxidative stress and dopaminergic neuron damage in organotypic substantia nigra cultures. Brain Res. Mol. Brain Res. 134 (2005) 109-118
95. Thiffault C., Aumont N., Quirion R., and Poirier J. Effect of MPTP and l-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65 (1995) 2725-2733
96. Thiffault C., Quirion R., and Poirier J. The effect of l-deprenyl, d-deprenyl and MDL72974 on mitochondrial respiration: a possible mechanism leading to an adaptive increase in superoxide dismutase activity. Brain Res. Mol. Brain Res. 49 (1997) 127-136
97. Thomas B., and Mohanakumar K.P. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J. Pineal Res. 36 (2003) 1-9
98. Thomas C.E., Huber E.W., and Ohlweiler D.F. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic. Biol. Med. 22 (1997) 733-737
99. ThyagaRajan S., Madden K.S., Kalvass J.C., Dimitrova S., Felten S.Y., and Felten D.L. l-deprenyl-induced increase in IL-2 and NK cell activity accompanies restoration of noradrenergic nerve fibers in the spleens of old F344 rats. J. Neuroimmunol. 92 (1998) 9-21
100. Thyagarajan S., Madden K.S., Stevens S.Y., and Felten D.L. Inhibition of tumor growth by l-deprenyl involves neural-immune interactions in rats with spontaneously developing mammary tumors. Anticancer Res. 19 (1999) 5023-5028
101. Turrens J.F., and Boveris A. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191 (1980) 421-427
102. Tyler D.D. Polarographic assay and intracellular distribution of superoxide dismutase in rat liver. Biochem J. 147 (1975) 493-504
103. Ungerstedt U., and Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res. 24 (1970) 485-493
104. Wadia J.S., Chalmers-Redman R.M., Ju W.J.H., Carlile G.W., Phillips J.L., Fraser A.D., and Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-) deprenyl. J. Neurosci. 18 (1998) 932-947
105. Waldmeier P.C., Boulton A.A., Cools A.R., Kato A.C., and Tatton W.G. Neurorescuing effects of the GAPDH ligand CGP 3466B. J. Neural Transm. Suppl. 60 (2000) 197-214
106. + in vivo. Eur. J. Pharmacol. 243 (1993) 241-247
107. + toxicity by deprenyl (selegiline). Ann. NY Acad. Sci. 738 (1994) 214-221
108. Wu R.M., Murphy D.L., and Chiueh C.C. Suppression of hydroxyl radical formation and protection of nigral neurons by l-deprenyl (selegiline). Ann. NY Acad. Sci. 786 (1996) 379-390
109. Wu R.M., Chen R.C., and Chiueh C.C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann. NY Acad. Sci. 899 (2000) 255-261
110. Wullner U., Luschmann P.A., and Schull J.B. Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. Neuroreport 7 (1996) 921-923
111. Yoneda F., Moto T., Sakae M., Ohde H., Knoll B., Miklya I., and Knoll J. Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain. Bioorg. Med. Chem. 5 (2001) 1197-1212
112. Yong V.W., Perry T.L., and Krisman A.A. Depletion of glutathione in brainstem of mice caused by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is prevented by antioxidant pretreatment. Neurosci. Lett. 63 (1986) 56-60
113. Zang L.Y., and Mishra H.P. EPR Kinetics studies of superoxide radicals generated during the autoxidation of 1-methyl-4-phenyl-2,3-dihydropyridine. J. Biol. Chem. 267 (1992) 23601-23608